77685-6

HIV 1 and 2 IgG Ab [Identifier] in Serum or Plasma by Immunoblot

Active

Term Description

This assay differentiates between HIV-1 and HIV-2 infections and is intended as a supplementary assay on specimens found to be reactive using an anti-HIV screening procedure. Five HIV-1 antigens are used in the testing: sgp120 and gp41, which detect HIV-1 specific antibodies, and p31, p24, and p17, which may also cross-react with antibodies to HIV-2. HIV-1 group O peptides are present in the HIV-1 sgp120 band. The antigens gp36 and sgp105 are used to detect HIV-2 antibodies. This term was created for, but not termed in use to, the submitter's INNO-LIA™ HIV I/II Score test kit, which is a line immunoassay, to confirm the presence of antibodies against the human immunodeficiency virus type 1 (HIV-1), including group O, and type 2 (HIV-2) in human serum or plasma.
Source: Regenstrief LOINC

Part Descriptions

LP190777-5 HIV 1 & 2 Ab.IgG
Human immunodeficiency virus (HIV) is categorized into two types, HIV-1 and HIV-2. Worldwide, most HIV infections are HIV-1, whereas HIV-2 largely has been confined to persons in or from West Africa (1,2). HIV-1 and HIV-2 have the same routes of transmission, and both can cause acquired immunodeficiency syndrome (AIDS) (3); however, HIV-2 infections should be differentiated from HIV-1 infections because they are less likely to cause AIDS and their clinical management differs (4,5). CDC's current surveillance case definition for HIV infection applies to both variants of HIV (6) but lacks criteria for differentiating between HIV-1 and HIV-2.

To enumerate and describe HIV-2 cases reported in the United States, a working case definition was developed. During 1988 through June 2010, a total of 242 HIV-2 cases were reported to CDC. Of these, 166 met the working definition. These HIV-2 cases were concentrated in the Northeast (66%, including 46% in New York City) and occurred primarily among persons born in West Africa (81%). Ninety-seven of the HIV-2 cases also had a positive HIV-1 immunoblot antibody test result (e.g., Western blot). Immunoblot antibody tests currently used to confirm HIV reactive screening tests do not contain reagents specific to HIV-2 and thus are not reliable for identification of HIV-2 infections (7). Additional testing specific to HIV-2 should be considered if HIV-1 test results are atypical or inconsistent with clinical findings, especially for persons from West Africa. If an HIV case is reported to the health department but subsequently identified as HIV-2, health-care providers should update the case report to reflect the correct type. As of June 2012, the Bio-Rad Multispot HIV-1/HIV-2 Rapid Test is FDA approved for distinguishing HIV1 from HIV2. Source: Centers for Disease Control and Prevention, LV Torian, et al. HIV-2 Infection Surveillance -- United States, 1987-2009. Morbidity and Mortality Weekly Report 60(29);985-988. July 29, 2011.

LP36650-7 HIV 1 & 2
Human immunodeficiency virus (HIV) is categorized into two types, HIV-1 and HIV-2. Worldwide, most HIV infections are HIV-1, whereas HIV-2 largely has been confined to persons in or from West Africa (1,2). HIV-1 and HIV-2 have the same routes of transmission, and both can cause acquired immunodeficiency syndrome (AIDS) (3); however, HIV-2 infections should be differentiated from HIV-1 infections because they are less likely to cause AIDS and their clinical management differs (4,5). CDC's current surveillance case definition for HIV infection applies to both variants of HIV (6) but lacks criteria for differentiating between HIV-1 and HIV-2.

To enumerate and describe HIV-2 cases reported in the United States, a working case definition was developed. During 1988 through June 2010, a total of 242 HIV-2 cases were reported to CDC. Of these, 166 met the working definition. These HIV-2 cases were concentrated in the Northeast (66%, including 46% in New York City) and occurred primarily among persons born in West Africa (81%). Ninety-seven of the HIV-2 cases also had a positive HIV-1 immunoblot antibody test result (e.g., Western blot). Immunoblot antibody tests currently used to confirm HIV reactive screening tests do not contain reagents specific to HIV-2 and thus are not reliable for identification of HIV-2 infections (7). Additional testing specific to HIV-2 should be considered if HIV-1 test results are atypical or inconsistent with clinical findings, especially for persons from West Africa. If an HIV case is reported to the health department but subsequently identified as HIV-2, health-care providers should update the case report to reflect the correct type. As of June 2012, the Bio-Rad Multispot HIV-1/HIV-2 Rapid Test is FDA approved for distinguishing HIV1 from HIV2. Source: Centers for Disease Control and Prevention, LV Torian, et al. HIV-2 Infection Surveillance -- United States, 1987-2009. Morbidity and Mortality Weekly Report 60(29);985-988. July 29, 2011.

Fully-Specified Name

Component: HIV 1 & 2 Ab.IgG
Property: Prid
Time: Pt
System: Ser/Plas
Scale: Nom
Method: IB

Additional Names

Short Name: HIV 1 & 2 IgG SerPl IB
Display Name: HIV 1 and 2 IgG IB Nom
Consumer Name Alpha Get Info: HIV 1 and 2 IgG antibody, Blood

Example Answer List: LL1996-9

Source: BIO-RAD

Answer	Code	Score	Answer ID
NonreactiveCopyright http://snomed.info/sct ID:131194007 Non-reactive (qualifier value)			LA15256-3
HIV-1 reactive			LA18330-3
HIV-2 reactive			LA18331-1
HIV Reactive (Undifferentiated)			LA18332-9
InvalidCopyright http://snomed.info/sct ID:455371000124106 Invalid result (qualifier value)			LA15841-2

Basic Attributes

Class: MICRO
Type: Laboratory
First Released: Version 2.52
Last Updated: Version 2.58
Change Reason: Correction: Changed from Property 'Pr' and Scale 'Ord' as the answers are not a ranked set of options.
Order vs. Observation: Both

Language Variants Get Info

Tag	Language	Translation
es-ES	Spanish (Spain)	HIV 1 y 2 IgG:Presencia o identidad:Punto temporal:Suero o Plasma:Nom:Inmunoblot (IB)
es-MX	Spanish (Mexico)	VIH 1 y 2 Ab.IgG:Presencia o identidad:Punto temporal:Suero o Plasma:Nominal:Inmunotransferencia
fr-CA	French (Canada)	VIH 1 & 2, IgG:Présence ou identité:Temps ponctuel:Sérum/Plasma:Nominal:Immunoblot
fr-FR	French (France)	VIH1 et VIH-2 Ac IgG:Identification:Ponctuel:Sérum/Plasma:Résultat nominal:Immunoblot
fr-BE	French (Belgium)	VIH 1 & 2 Anticorps. IgG:Présence ou identité:Temps ponctuel:Sérum/Plasma:Nominal:Immunoblot Synonyms: Anticorps HIV HIV 1 HIV 1&2 HIV 1+2
it-IT	Italian (Italy)	HIV 1 & 2 Ab.IgG:Prid:Pt:Siero/Plasma:Nom:IB Synonyms: anticorpi IgG anticorpo Immunoblot (IB) Microbiologia Plasma Presenza o Identità Punto nel tempo (episodio) Siero Siero o Plasma
nl-NL	Dutch (Netherlands)	HIV 1 & 2 As.IgG:identificator:moment:serum of plasma:nominaal:immunoblotting Synonyms: antistof; antilichaam IB
pl-PL	Polish (Poland)	HIV 1 i 2 Ab.IgG:wykrycie lub identyfikacja:punkt w czasie:surowica lub osocze:cecha:immunoblotting Synonyms: IgG Ludzki wirus niedoboru odporności typu 1 Ludzki wirus niedoboru odporności typu 1 i 2 Ludzki wirus niedoboru odporności typu 1+2 Przeciwciała do HIV 1 i 2 Przeciwciała do HIV 1+2 Przeciwciała IgG do HIV 1 i 2 Przeciwciała IgG do HIV 1+2
ru-RU	Russian (Russian Federation)	HIV 1 & 2 Ат.IgG:ПрИд:ТчкВрм:Сыв/Плаз:Ном:ИБ Synonyms: Антитело ВИЧ ВИЧ 1 ВИЧ 1 и 2 ВИЧ 1+2 Иммуноблот (ИБ) Номинальный;Именной Плазма Присутствие или Идентификация Сыворотка Сыворотка или Плазма Точка во времени;Момент
tr-TR	Turkish (Turkey)	HIV 1 ve 2 Ab.IgG:MevcKimlik:Zmlı:Ser/Plaz:Snf:IB Synonyms: Ak Ak.IgG
zh-CN	Chinese (China)	HIV 1 型与 2 型抗体.IgG:存在与否或特征标识:时间点:血清/血浆:名义型:免疫印迹法 Synonyms: Ⅰ Ⅱ Ab.IgG;IgG;抗体 IgG Ab;自身抗体 AIDS;AIDS 病毒;人类免疫缺陷病毒;人类免疫缺陷病毒（Human immunodeficiency virus，HIV）;爱滋病;艾滋病;艾滋病病毒;获得性免疫缺陷综合征;获得性免疫缺陷综合征（Acquired Immure Deficiency Syndrome，AIDS，艾滋病） HIV 1 & 2 Ab HIV 1+2 Ab HIV 1+2 Ab.IgG HIV1;HTLV 3;HTLV III;人类免疫缺陷病毒 1 型;人类免疫缺陷病毒 I 型;HIV 1 型（人类免疫缺陷病毒 1 型、人类免疫缺陷病毒 I 型、人免疫缺陷病毒 1 型、人免疫缺陷病毒 I 型、HIV I、HIV I 型、艾滋病病毒 I 型） I II 人类免疫缺陷病毒 1 & 2 型 Ab 人类免疫缺陷病毒 1 & 2 型抗体人类免疫缺陷病毒 1 与 2 型 Ab 人类免疫缺陷病毒 1 与 2 型;HIV（人类免疫缺陷病毒、人免疫缺陷病毒、艾滋病病毒） 1 型（I 型）与 2 型（II 型）人类免疫缺陷病毒 1 与 2 型抗体人类免疫缺陷病毒 1+2 型 Ab 人类免疫缺陷病毒 1+2 型 Ab.IgG 人类免疫缺陷病毒 1+2 型 IgG 人类免疫缺陷病毒 1+2 型;HIV 1+2 型（人类免疫缺陷病毒 1+2 型、人类免疫缺陷病毒 I+II 型、人免疫缺陷病毒 1+2 型、人免疫缺陷病毒 I+II 型、HIV I+II、HIV I+II 型、艾滋病病毒 I+II 型）人类免疫缺陷病毒 1+2 型抗体人类免疫缺陷病毒 1+2 型抗体.IgG 免疫印迹;西部印迹法;Immunoblot;immunoblotting;IB 免疫球蛋白 G 分类型应答;分类型结果;名义性;名称型;名词型;名词性;标称性;没有自然次序的名义型或分类型应答存在;存在与否;特征标识;身份;身份标识微生物学;微生物学试验;微生物学试验（培养、DNA、抗原及抗体）时刻;随机;随意;瞬间血清或血浆

LOINC Terminology Service (API) using HL7^® FHIR^® Get Info

CodeSystem lookup: https://fhir.loinc.org/CodeSystem/$lookup?system=http://loinc.org&code=77685-6

Third Party Copyright

This material includes SNOMED Clinical Terms® (SNOMED CT®) which is used by permission of the International Health Terminology Standards Development Organisation (IHTSDO) under license. All rights reserved. SNOMED CT® was originally created by The College of American Pathologists. "SNOMED" and "SNOMED CT" are registered trademarks of the IHTSDO.

This material includes content from the US Edition to SNOMED CT, which is developed and maintained by the U.S. National Library of Medicine and is available to authorized UMLS Metathesaurus Licensees from the UTS Downloads site at https://uts.nlm.nih.gov.

Use of SNOMED CT content is subject to the terms and conditions set forth in the SNOMED CT Affiliate License Agreement. It is the responsibility of those implementing this product to ensure they are appropriately licensed and for more information on the license, including how to register as an Affiliate Licensee, please refer to http://www.snomed.org/snomed-ct/get-snomed-ct or info@snomed.org<mailto:info@snomed.org>. This may incur a fee in SNOMED International non-Member countries.

LOINC Copyright

Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright © 1995-2024, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. See https://loinc.org/license for the full LOINC copyright and license.